-
ProteoXplore
Integration of multi-omics data
ProteoXplore is an integrated platform built for the comprehensive analysis of patient data, employing cutting-edge proteomics and multiomics technologies to discover potential drug targets and meticulously scrutinize the characteristics of drug candidates. To achieve this, AMC Sciences systematically constructs precisely defined disease cohorts based on clinically unmet needs. The integration and and analysis of genomics, transcriptomics, proteomics, and metabolomics and clinical data are central to this process.
This approach allows for the identification of specific targets closely aligned with patient requirements, thereby facilitating the discovery of highly effective drug targets. ProteoXplore, through its pioneering methodologies, plays a pivotal role in advancing the development of innovative drugs for a spectrum of diseases.
New drug development through ProteoXplore platform
-
-
SurvivAb
Cancer Survivor-derived Anti-Cancer Antibodies Discovery Platform
SurvivAb is an instrumental platform dedicated to the exploration and advancement of novel anti-cancer antibodies selected from the blood of cancer survivors. The platform conducts a comprehensive analysis of various clinical indicators for different types of refractory cancers, obtains consent from carefully selected survivors to secure blood samples, and employs antibody phage display techniques to select antibodies with a specific affinity for cancer cells. The platform also utilizes patented antigen discovery technology, enabling the identification of genes associated with antigens bound by antibodies and facilitating epitope mapping.
Notably, SurvivAb has successfully identified three novel antibody drug candidates for solid tumors and is actively screening various cancer types. Through collaborative partnerships with research and development allies, the platform is expediting joint efforts to bring these candidates to fruition.
SurvivAb accelerates the development of therapeutic antibodies to address the clinical unmet needs of diverse cancer types.
